|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-37 (IL-37) is a fundamental natural suppressor of innate immunity and inflammatory responses in several autoimmune diseases.
|
31557634 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thence, IL-37 has anti-inflammatory action in some diseases including cancer, autoimmune diseases, cardiovascular diseases and infectious diseases.
|
31633447 |
2020 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risankizumab, an anti-interleukin-23 monoclonal antibody, achieved significantly (P < 0.001) greater Psoriasis Area and Severity Index (PASI) and static Physician Global Assessment (sPGA) clear or almost clear (0/1) responses than adalimumab in a phase III trial in patients with moderate-to-severe psoriasis.
|
31502263 |
2020 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Guselkumab, an interleukin-23 antagonist, is approved for self-administration with the UltraSafe Plus™ syringe to treat moderate-to-severe plaque-type psoriasis.
|
30887876 |
2020 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
|
31465593 |
2020 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Objective:</b> Risankizumab (Skyrizi), an interleukin-23 (IL-23) antagonist, was approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in April 2019.
|
31672037 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Thence, IL-37 has anti-inflammatory action in some diseases including cancer, autoimmune diseases, cardiovascular diseases and infectious diseases.
|
31633447 |
2020 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study is to detect the dynamic expression of interleukin-23 (IL-23) in ApoE<sup>-/-</sup> mice at different ages and to further examine the effects of anti-IL-23 therapy on atherosclerosis development.
|
31264927 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although research concerning the role of IL-37 and its mechanism in atherosclerosis is relatively scant, there are a number of well-known atherosclerotic processes that this cytokine can mediate with the potential of modulating the disease progression itself.
|
28988706 |
2019 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, transgenic overexpression of IL-37 improves cardiac infarct and attenuates atherosclerosis plaque expansion.
|
31292092 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, this study indicated that IL-37 inhibited the maturation of DCs via the IL-1R8-TLR4-NF-κB pathway and attenuated atherosclerosis in ApoE<sup>-/-</sup> mice.
|
31125703 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-23 (IL-23) has been associated with atherosclerosis in both humans and animal models with contradictory results.
|
31237437 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the validation cohort, when plasma IL-37 in RA patients compared with that in SLE, OA, gout, pSS and AS patients, the AUC was 0.86, 0.87, 0.91, 0.87, 0.92, respectively.
|
30843355 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
An emerging role of interleukin-23 in rheumatoid arthritis.
|
31072166 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, interleukin-23 (IL-23), and IL-17 are vital to the pathogenesis of RA.
|
30856393 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction to: Critical role of interleukin-23 in development of asthma promoted by cigarette smoke.
|
31119301 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Critical role of interleukin-23 in development of asthma promoted by cigarette smoke.
|
31020341 |
2019 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, increasing evidence confirms that IL-37 expression is aberrant in asthma, AR and AD, which indicates that IL-37 may also play essential roles in allergic diseases.
|
31672283 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data highlight the importance of TSLP in IL-37-mediated protective role in asthma.
|
30537285 |
2019 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlation between the pathogenesis of bronchial asthma and serum expressions of IL-4, IL-12, IL-37 and 25-(OH)D.
|
31184089 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, transgenic overexpression of IL-37 improves cardiac infarct and attenuates atherosclerosis plaque expansion.
|
31292092 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study is to detect the dynamic expression of interleukin-23 (IL-23) in ApoE<sup>-/-</sup> mice at different ages and to further examine the effects of anti-IL-23 therapy on atherosclerosis development.
|
31264927 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although research concerning the role of IL-37 and its mechanism in atherosclerosis is relatively scant, there are a number of well-known atherosclerotic processes that this cytokine can mediate with the potential of modulating the disease progression itself.
|
28988706 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-23 (IL-23) has been associated with atherosclerosis in both humans and animal models with contradictory results.
|
31237437 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, this study indicated that IL-37 inhibited the maturation of DCs via the IL-1R8-TLR4-NF-κB pathway and attenuated atherosclerosis in ApoE<sup>-/-</sup> mice.
|
31125703 |
2019 |